Abstract:Rare eye diseases encompass a broad spectrum of genetic anomalies with or without additional extraocular manifestations. Genetic eye disorders in pediatric patients often lead to severe visual impairments. Therefore, a challenge of gene therapy is to provide better vision to these affected children. In recent years, inherited retinal diseases, inherited optic neuropathies, and corneal dystrophies have dominated discussions to establish gene and cell replacement therapies for these diseases. Gene therapy involves the transfer of genetic material to remove, replace, repair, or introduce a gene, or to overexpress a protein, whose activity would have a therapeutic impact. For the majority of anterior segment diseases, these studies are still emerging at a preclinical stage; however, for inherited retinal disorders, translation has been reached, leading to the introduction of the first gene therapies into clinical practice. In the past decade, the first gene therapy for biallelic RPE65-mediated inherited retinal dystrophy has been developed and the FDA and EMA both approved ocular gene therapy. Other promising approaches by intravitreal injection have been investigated such as in CEP290-Leber congenital amaurosis. Various techniques of gene therapies include gene supplementation, CRISPR-based genome editing, as well as RNA modulation and optogenetics. Optogenetic therapies deliver light-activated ion channels to surviving retinal cell types in order to restore photosensitivity. Beyond retinal function, ataluren, a nonsense mutation suppression therapy, enables ribosomal read-through of mRNA containing premature termination codons, resulting in the production of a full-length protein. An ophthalmic formulation was recently evaluated with the aim of repairing corneal damage, pending new clinical studies. However, various congenital disorders exhibit severe developmental defects or cell loss at birth, limiting the potential for viral gene therapy. Therefore mutation-independent strategies seem promising for maintaining the survival of photoreceptors or for restoring visual function. Restoring vision in children with gene therapy continues to be a challenge in ophthalmology. © 2023 Published by Elsevier Masson SAS on behalf of French Society of Pediatrics.

Ocular Gene Therapy: Literature Review

Advances in Gene Therapy for Diseases of the Eye

Lentiviral Vectors for Ocular Gene Therapy

Gene-based therapeutic tools in the treatment of Cornea Disease.

Progress and Prospects of Gene Therapy in Ophthalmology from 2000 to 2022: A Bibliometric Analysis

A 2020 vision of ocular gene therapy

AAV for Gene Therapy in Ocular Diseases: Progress and Prospects

Gene Therapy for Ocular Diseases Meditated by Ultrasound and Microbubbles (Review)

The concept of gene therapy for glaucoma: the dream that has not come true yet

A Mini-Review on Gene Therapy in Glaucoma and Future Directions

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy

Seeing the Future: A Review of Ocular Therapy

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Gene therapy for glaucoma: Targeting key mechanisms

Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: progress towards non-viral systems

Update on gene therapies in pediatric ophthalmology

Genetic engineering and the eye

Use of gene therapy for optic nerve protection: Current concepts

Frequency and Pattern of Worldwide Ocular Gene Therapy Clinical Trials up to 2022

Genome editing in the treatment of ocular diseases

Ultrasound Targeted Microbubble Destruction-Mediated Gene Delivery System: Application to Therapy for Ocular Disease